Advertisement

Gilead Sciences, Inc. GILD

Set alert

Price alert · GILD

All alert types
170.33 USD -0.35 -0.21%

At close · Nov 2

171.22 +0.89 +0.52%

After hours · Nov 2, 6:14 PM ET

Bid
170.35 × 1
Ask
170.39 × 1
166.38 Day range 172.61
116.88 52-week range 175.65
YTD
+38.77%
1 year
+42.19%
Open
169.85
Prev close
170.68
Mkt cap
211.27B
Vol
8.58M
Avg vol
6.12M
EPS
-3.13
P/E
0.00
Div yield
1.92%
More statistics
Low
166.38
High
172.61
Forward P/E
16.88
Beta
0.37
Short ratio
3.40
Inst. own
92.01%
Dividend
3.28
Ex-div date
Dec 14, 2026
Earnings
Feb 9, 2027
50-d avg
150.87
200-d avg
139.88
1y target
172.50

1m chart

Chart tools
Interval

Built from the cached one-day intraday bars.

Signals (134)
NameTimeAgo
SMA: BearishNov 2, 3:55 PM2 hours ago
SMA: BearishNov 2, 3:55 PM2 hours ago
MACD: Sell SignalNov 2, 3:55 PM2 hours ago
SMA: BullishNov 2, 3:45 PM2 hours ago
SMA: BullishNov 2, 3:44 PM2 hours ago
SMA: BearishNov 2, 3:43 PM2 hours ago
SMA: BearishNov 2, 3:43 PM2 hours ago
SMA: BullishNov 2, 3:37 PM2 hours ago
MACD: Buy SignalNov 2, 3:31 PM2 hours ago
SMA: BullishNov 2, 3:30 PM2 hours ago
RSI: OversoldNov 2, 3:29 PM2 hours ago
RSI: OversoldNov 2, 3:27 PM2 hours ago
SMA: BearishNov 2, 3:12 PM3 hours ago
SMA: BearishNov 2, 3:12 PM3 hours ago
SMA: BullishNov 2, 3:11 PM3 hours ago
SMA: BearishNov 2, 3:10 PM3 hours ago
MACD: Sell SignalNov 2, 3:10 PM3 hours ago
SMA: BullishNov 2, 3:08 PM3 hours ago
MACD: Buy SignalNov 2, 3:08 PM3 hours ago
SMA: BearishNov 2, 3:07 PM3 hours ago
MACD: Sell SignalNov 2, 3:07 PM3 hours ago
SMA: BullishNov 2, 3:06 PM3 hours ago
SMA: BearishNov 2, 3:05 PM3 hours ago
MACD: Buy SignalNov 2, 2:58 PM3 hours ago
SMA: BullishNov 2, 2:56 PM3 hours ago
SMA: BullishNov 2, 2:55 PM3 hours ago
SMA: BearishNov 2, 2:52 PM3 hours ago
SMA: BearishNov 2, 2:51 PM3 hours ago
MACD: Sell SignalNov 2, 2:51 PM3 hours ago
SMA: BullishNov 2, 2:31 PM3 hours ago
SMA: BearishNov 2, 2:30 PM3 hours ago
MACD: Buy SignalNov 2, 2:28 PM3 hours ago
SMA: BullishNov 2, 2:27 PM3 hours ago
SMA: BearishNov 2, 2:26 PM3 hours ago
SMA: BullishNov 2, 2:25 PM3 hours ago
SMA: BullishNov 2, 2:25 PM3 hours ago
SMA: BearishNov 2, 2:19 PM3 hours ago
MACD: Sell SignalNov 2, 2:15 PM4 hours ago
RSI: OverboughtNov 2, 2:03 PM4 hours ago
SMA: BullishNov 2, 1:59 PM4 hours ago
SMA: BullishNov 2, 1:59 PM4 hours ago
SMA: BearishNov 2, 1:58 PM4 hours ago
SMA: BearishNov 2, 1:58 PM4 hours ago
SMA: BullishNov 2, 1:53 PM4 hours ago
SMA: BullishNov 2, 1:53 PM4 hours ago
MACD: Buy SignalNov 2, 1:53 PM4 hours ago
MACD: Sell SignalNov 2, 1:51 PM4 hours ago
SMA: BearishNov 2, 1:50 PM4 hours ago
SMA: BearishNov 2, 1:49 PM4 hours ago
MACD: Buy SignalNov 2, 1:46 PM4 hours ago
SMA: BullishNov 2, 1:43 PM4 hours ago
SMA: BullishNov 2, 1:43 PM4 hours ago
SMA: BearishNov 2, 1:36 PM4 hours ago
MACD: Sell SignalNov 2, 1:35 PM4 hours ago
SMA: BullishNov 2, 1:19 PM4 hours ago
SMA: BearishNov 2, 1:16 PM5 hours ago
SMA: BearishNov 2, 1:16 PM5 hours ago
SMA: BullishNov 2, 1:13 PM5 hours ago
SMA: BearishNov 2, 1:12 PM5 hours ago
SMA: BullishNov 2, 1:11 PM5 hours ago
SMA: BullishNov 2, 1:11 PM5 hours ago
MACD: Buy SignalNov 2, 1:11 PM5 hours ago
SMA: BearishNov 2, 1:10 PM5 hours ago
MACD: Sell SignalNov 2, 1:10 PM5 hours ago
MACD: Buy SignalNov 2, 1:07 PM5 hours ago
SMA: BullishNov 2, 1:05 PM5 hours ago
SMA: BearishNov 2, 1:00 PM5 hours ago
SMA: BullishNov 2, 12:59 PM5 hours ago
SMA: BearishNov 2, 12:51 PM5 hours ago
SMA: BearishNov 2, 12:51 PM5 hours ago
SMA: BullishNov 2, 12:49 PM5 hours ago
SMA: BearishNov 2, 12:48 PM5 hours ago
SMA: BullishNov 2, 12:47 PM5 hours ago
MACD: Sell SignalNov 2, 12:41 PM5 hours ago
RSI: OverboughtNov 2, 12:34 PM5 hours ago
MACD: Buy SignalNov 2, 12:29 PM5 hours ago
RSI: OverboughtNov 2, 12:29 PM5 hours ago
SMA: BullishNov 2, 12:22 PM5 hours ago
SMA: BearishNov 2, 12:20 PM5 hours ago
MACD: Sell SignalNov 2, 12:20 PM5 hours ago
RSI: OverboughtNov 2, 12:15 PM6 hours ago
MACD: Buy SignalNov 2, 12:14 PM6 hours ago
SMA: BullishNov 2, 12:07 PM6 hours ago
SMA: BearishNov 2, 12:03 PM6 hours ago
SMA: BullishNov 2, 12:02 PM6 hours ago
SMA: BearishNov 2, 12:00 PM6 hours ago
MACD: Sell SignalNov 2, 12:00 PM6 hours ago
MACD: Buy SignalNov 2, 11:52 AM6 hours ago
RSI: OverboughtNov 2, 11:52 AM6 hours ago
SMA: BullishNov 2, 11:47 AM6 hours ago
SMA: BearishNov 2, 11:43 AM6 hours ago
MACD: Sell SignalNov 2, 11:43 AM6 hours ago
RSI: OverboughtNov 2, 11:36 AM6 hours ago
RSI: OverboughtNov 2, 11:30 AM6 hours ago
MACD: Buy SignalNov 2, 11:21 AM6 hours ago
SMA: BullishNov 2, 11:20 AM6 hours ago
SMA: BullishNov 2, 11:20 AM6 hours ago
MACD: Sell SignalNov 2, 11:14 AM7 hours ago
SMA: BearishNov 2, 11:13 AM7 hours ago
SMA: BearishNov 2, 11:12 AM7 hours ago
SMA: BullishNov 2, 11:06 AM7 hours ago
SMA: BullishNov 2, 11:06 AM7 hours ago
MACD: Buy SignalNov 2, 11:06 AM7 hours ago
SMA: BearishNov 2, 11:05 AM7 hours ago
SMA: BearishNov 2, 11:05 AM7 hours ago
SMA: BullishNov 2, 11:04 AM7 hours ago
SMA: BearishNov 2, 11:03 AM7 hours ago
SMA: BullishNov 2, 11:01 AM7 hours ago
SMA: BearishNov 2, 10:58 AM7 hours ago
MACD: Sell SignalNov 2, 10:58 AM7 hours ago
SMA: BearishNov 2, 10:55 AM7 hours ago
SMA: BullishNov 2, 10:47 AM7 hours ago
SMA: BullishNov 2, 10:47 AM7 hours ago
SMA: BearishNov 2, 10:43 AM7 hours ago
SMA: BearishNov 2, 10:41 AM7 hours ago
SMA: BullishNov 2, 10:38 AM7 hours ago
SMA: BullishNov 2, 10:37 AM7 hours ago
MACD: Buy SignalNov 2, 10:37 AM7 hours ago
RSI: OversoldNov 2, 10:34 AM7 hours ago
MACD: Sell SignalNov 2, 10:33 AM7 hours ago
SMA: BearishNov 2, 10:28 AM7 hours ago
MACD: Buy SignalNov 2, 10:22 AM7 hours ago
SMA: BullishNov 2, 10:21 AM7 hours ago
RSI: OversoldNov 2, 10:18 AM8 hours ago
RSI: OversoldNov 2, 10:14 AM8 hours ago
SMA: BearishNov 2, 10:04 AM8 hours ago
MACD: Sell SignalNov 2, 10:04 AM8 hours ago
SMA: BullishNov 2, 10:03 AM8 hours ago
SMA: BearishNov 2, 10:01 AM8 hours ago
SMA: BearishNov 2, 10:00 AM8 hours ago
SMA: BullishNov 2, 9:57 AM8 hours ago
SMA: BearishNov 2, 9:53 AM8 hours ago
SMA: BullishNov 2, 9:48 AM8 hours ago
SMA: BearishNov 2, 9:40 AM8 hours ago

Key statistics

Market cap
211.27B
Enterprise value
229.90B
Trailing P/E
0.00
Forward P/E
16.88
PEG ratio
2.52
Price / sales
6.82
Price / book
16.21
EPS (TTM)
-3.13
Beta
0.37
Dividend yield
1.92%
Payout ratio
43.46%
Profit margin
-12.46%
Revenue (TTM)
30.99B
Revenue growth
6.80%
Free cash flow
10.68B
Total cash
7.95B
Total debt
26.23B
Return on equity
-22.45%
Shares outstanding
1.24B
Short % of float
1.63%
50-day average
150.87
200-day average
139.88

Analyst view

Consensus: buy

Buy
Price target (mean) 172.50 +1.3% upside
Target (low)
131.00
Target (mean)
172.50
Target (high)
200.00
Ratings (0m) 28 22 buy · 5 hold · 1 sell
  • Strong buy6
  • Buy16
  • Hold5
  • Sell0
  • Strong sell1

Next earnings

Feb 9, 2027

Expected Feb 9, 2027. Consensus EPS estimate 1.07.

Earnings history

Financials — quick view

All financials
GILD Revenue — quarterly 8.30B
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
GILD Net income — quarterly 2.43B
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
GILD EPS — quarterly 1.96
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026

Earnings

GILD recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 9, 2027Dec 30, 20261.39———
Oct 29, 2026Sep 30, 20262.192.55+0.36+16.44%
Aug 3, 2026Jun 30, 2026-7.25-6.75+0.50+6.90%
May 7, 2026Mar 31, 20261.912.03+0.12+6.28%
Feb 10, 2026Dec 31, 20251.811.86+0.05+2.76%
Oct 30, 2025Sep 30, 20252.132.47+0.34+15.96%

Upgrades / downgrades

GILD analyst upgrades and downgrades
DateFirmActionFromTo
Oct 30, 2026UBSmainBuyBuy
Oct 30, 2026JP MorganmainOverweightOverweight
Oct 30, 2026CitigroupmainBuyBuy
Oct 30, 2026ScotiabankmainSector OutperformSector Outperform
Oct 30, 2026TD CowenmainBuyBuy
Oct 30, 2026Morgan StanleymainOverweightOverweight

About Gilead Sciences, Inc.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company has a partnership with Pan American Health Organization (PAHO) to accelerate access to lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP) across all PAHO member states in Latin America and the Caribbean. The company was incorporated in 1987 and is headquartered in Foster City, California.

Sector
Healthcare
Industry
Drug Manufacturers - General
Country
United States
Website
gilead.com

News

Your note

Sign in to keep a note on GILD — it syncs with the Stock Master app.

Insider holders

GILD insider holders
InsiderRelationLatest transactionDateShares held
BARTON JACQUELINE KDirectorStock Award(Grant)Apr 29, 202627,202
BERGER DIETMAR P.OfficerConversion of Exercise of derivative securitySep 9, 202619,522
DICKINSON ANDREW DChief Financial OfficerSaleSep 14, 2026164,096
MANWANI HARISHDirectorStock Award(Grant)Apr 29, 202615,015
MERCIER JOHANNAOfficerSaleSep 14, 2026116,684
O'DAY DANIEL PATRICKChief Executive OfficerConversion of Exercise of derivative securitySep 9, 2026581,683

Institution ownership

GILD institution ownership
Holder% heldSharesValueReported
Blackrock Inc.9.83%121,844,10820.75BJun 29, 2026
Vanguard Capital Management LLC6.54%81,091,73413.81BJun 29, 2026
FMR, LLC5.39%66,870,81611.39BJun 29, 2026
State Street Corporation4.94%61,216,55210.43BJun 29, 2026
Capital World Investors3.31%40,988,9756.98BJun 29, 2026
Invesco Ltd.3.21%39,819,1516.78BJun 29, 2026

Fund ownership

GILD fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.18%39,416,8936.71BJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard 500 Index Fund2.59%32,173,7505.48BJun 29, 2026
Invesco QQQ Trust, Series 12.09%25,899,6724.41BSep 29, 2026
Dodge & Cox Funds-Dodge & Cox Stock Fund1.39%17,282,8122.94BJun 29, 2026
iShares Trust-iShares Core S&P 500 ETF1.33%16,522,3152.81BSep 29, 2026
Fidelity Concord Street Trust-Fidelity 500 Index Fund1.30%16,116,6982.75BAug 30, 2026
Advertisement